{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:30Z","timestamp":1780038150434,"version":"3.53.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the short-term impact of finerenone combined with guideline-directed medical therapy (GDMT) on cardiac structure, function, and renal parameters in Chinese patients with post-myocardial infarction heart failure in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective observational cohort study, 67 patients received finerenone plus optimized GDMT for 3 months. Changes were assessed using echocardiography (measuring LVEF, GLS, left atrial strain and volume index), laboratory tests (NT-proBNP, serum potassium, renal function, urinary albumin-to-creatinine ratio [UACR]), and functional assessments (6-min walk test, Minnesota Living with Heart Failure Questionnaire).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Treatment significantly improved cardiac function and structure. LVEF increased from 49 (2)% to 53 (2)% (P &amp;lt; 0.001), GLS improved from 14 (1)% to 16 (1)% (P &amp;lt; 0.001), and left atrial reservoir strain increased from 27 (2)% to 32 (2)% (P &amp;lt; 0.001). Structural reverse remodeling was evidenced by reduced left ventricular end-diastolic diameter (54.85 [1.08] to 52.85 [0.96] mm, P &amp;lt; 0.001) and left atrial volume index (38.78 [2.69] to 36.25 [2.61] mL\/m\n                      <jats:sup>2<\/jats:sup>\n                      , P &amp;lt; 0.001). Concurrently, a significant reduction in UACR was observed from 3.41 \u00b1 1.52\u00a0mg\/g to 2.76 \u00b1 0.90\u00a0mg\/g (P &amp;lt; 0.001). Clinically, NT-proBNP decreased from 1,249 \u00b1 1,251 to 431 \u00b1 319\u00a0pg\/mL (P &amp;lt; 0.001), 6-min walk distance increased by 41.11\u00a0m (P &amp;lt; 0.001), and quality of life scores improved (a reduction of 11.59 points, P &amp;lt; 0.001). Serum potassium and renal function (serum creatinine) remained stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of 67 post-myocardial infarction heart failure patients, adding finerenone to GDMT for 3 months was associated with significant improvements in cardiac structure and function, a reduction in UACR, and better functional capacity and quality of life. Nevertheless, due to the single-arm design, these findings are exploratory and hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1754115","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:11:14Z","timestamp":1780035074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Finerenone combined with guideline-directed medical therapy in patients with post-myocardial infarction heart failure: a real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Di","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Xia","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases-clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"sfae346","DOI":"10.1093\/ckj\/sfae346","article-title":"Clinical implications of mineralocorticoid receptor overactivation","volume":"18","author":"El Mouhayyar","year":"2025","journal-title":"Clin. Kidney J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.13144","article-title":"Heart failure after myocardial infarction: incidence and predictors","volume":"8","author":"Jenca","year":"2021","journal-title":"Esc. Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur. Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41440-025-02175-2","article-title":"Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD","volume":"48","author":"Sato","year":"2025","journal-title":"Hypertens. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"","journal-title":"Eur. J. Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur. J. Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","author":"Writing Committee","year":"2022","journal-title":"J. Card. Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1476029","DOI":"10.3389\/fcvm.2024.1476029","article-title":"A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist","volume":"11","author":"Zhai","year":"2024","journal-title":"Front. Cardiovasc Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1476976","DOI":"10.3389\/fcvm.2024.1476976","article-title":"Vericiguat combined with \u201cnew quadruple\u201d therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study","volume":"11","author":"Zhao","year":"2024","journal-title":"Front. Cardiovasc Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1754115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:11:14Z","timestamp":1780035074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1754115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":21,"alternative-id":["10.3389\/fphar.2026.1754115"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1754115","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1754115"}}